From 10-Valent to 21-Valent Pneumococcal Conjugate Vaccines: Divergent Global Pathways and Future Directions for India

Kompithra, R.Z.; Varghese, R.; Muruganantham, G.; Mathew, G.; Veeraraghavan, B.; Kompithra, R.Z; Varghese, R; Muruganantham, G; Mathew, G; Veeraraghavan, B

doi:10.1007/s13312-026-00331-6

Home

>

Section

>

Chapter

From 10-Valent to 21-Valent Pneumococcal Conjugate Vaccines: Divergent Global Pathways and Future Directions for India

Kompithra, R.Z.; Varghese, R.; Muruganantham, G.; Mathew, G.; Veeraraghavan, B.

Indian Pediatrics 2026

2026

ISSN/ISBN: 0974-7559

PMID: 42081063

DOI: 10.1007/s13312-026-00331-6
Accession: 106032461

Full-Text Article emailed within 0-6 h

Payments are secure & encrypted

Summary

Pneumococcal conjugate vaccines (PCVs) have greatly reduced invasive pneumococcal disease worldwide, though outcomes vary with the serotype formulation and regional context. India's introduction of indigenous 10-valent PCV into its Universal Immunization Program (UIP) was a major milestone, differing from the earlier globally available PCV10 by including serotypes 19A and 6A-both of which have been linked to antimicrobial resistance (AMR) in countries such as Belgium and Brazil. This review synthesizes global vaccine experiences, explores serotype biology, cross-protection, and the emergence of non-vaccine types, and considers the spectrum of higher-valency options (PCV14, PCV20, and PCV21). India's pediatric PCV coverage has expanded rapidly, though unevenly, while adult uptake remains limited. While indigenous PCV10 introduction and scale-up, followed by indigenous PCV14 introduction seems a pragmatic policy for India's UIP today, sustained genomic and AMR surveillance, plus eventual transitions to broader PCVs, will be essential for long-term, adaptable immunization strategies.